Literature DB >> 25263480

Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.

Katharina Huber1, Annette Feuchtinger, Daniela M Borgmann, Zhoulei Li, Michaela Aichler, Stefanie M Hauck, Horst Zitzelsberger, Markus Schwaiger, Ulrich Keller, Axel Walch.   

Abstract

Drug efficacy strongly depends on the presence of the drug substance at the target site. As vascularization is an important factor for the distribution of drugs in tissues, we analyzed drug distribution as a function of blood vessel localization in tumor tissue. To explore distribution of the anticancer drugs afatinib, erlotinib, and sorafenib, a combined approach of matrix-assisted laser desorption/ionization (MALDI) drug imaging and immunohistochemical vessel staining was applied and examined by digital image analysis. The following two xenograft models were investigated: (1) mice carrying squamous cell carcinoma (FaDu) xenografts (ntumor = 13) were treated with afatinib or erlotinib, and (2) sarcoma (A673) xenograft bearing mice (ntumor = 8) received sorafenib treatment. MALDI drug imaging revealed a heterogeneous distribution of all anticancer drugs. The tumor regions containing high drug levels were associated with a higher degree of vascularization than the regions without drug signals (p < 0.05). When correlating the impact of blood vessel size to drug abundance in the sarcoma model, a higher amount of small vessels was detected in the tumor regions with high drug levels compared to the tumor regions with low drug levels (p < 0.05). With the analysis of coregistered MALDI imaging and CD31 immunohistochemical data by digital image analysis, we demonstrate for the first time the potential of correlating MALDI drug imaging and immunohistochemistry. Here we describe a specific and precise approach for correlating histological features and pharmacokinetic properties of drugs at microscopic level, which will provide information for the improvement of drug design, administration formula or treatment schemes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25263480     DOI: 10.1021/ac502177y

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  11 in total

1.  Identification of Biomarkers of Necrosis in Xenografts Using Imaging Mass Spectrometry.

Authors:  Roberto Fernández; Jone Garate; Sergio Lage; Silvia Terés; Mónica Higuera; Joan Bestard-Escalas; Daniel H López; Francisca Guardiola-Serrano; Pablo V Escribá; Gwendolyn Barceló-Coblijn; José A Fernández
Journal:  J Am Soc Mass Spectrom       Date:  2015-09-25       Impact factor: 3.109

Review 2.  MALDI Imaging mass spectrometry: current frontiers and perspectives in pathology research and practice.

Authors:  Michaela Aichler; Axel Walch
Journal:  Lab Invest       Date:  2015-01-26       Impact factor: 5.662

Review 3.  Recent developments in multiplexing techniques for immunohistochemistry.

Authors:  Angela R Dixon; Cédric Bathany; Michael Tsuei; Joshua White; Kate F Barald; Shuichi Takayama
Journal:  Expert Rev Mol Diagn       Date:  2015-08-06       Impact factor: 5.225

4.  Optimized Protocol To Analyze Changes in the Lipidome of Xenografts after Treatment with 2-Hydroxyoleic Acid.

Authors:  Roberto Fernández; Jone Garate; Sergio Lage; Silvia Terés; Mónica Higuera; Joan Bestard-Escalas; M Laura Martin; Daniel H López; Francisca Guardiola-Serrano; Pablo V Escribá; Gwendolyn Barceló-Coblijn; José A Fernández
Journal:  Anal Chem       Date:  2015-12-15       Impact factor: 6.986

5.  Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.

Authors:  Silvia Giordano; Massimo Zucchetti; Alessandra Decio; Marta Cesca; Ilaria Fuso Nerini; Marika Maiezza; Mariella Ferrari; Simonetta Andrea Licandro; Roberta Frapolli; Raffaella Giavazzi; D'Incalci Maurizio; Enrico Davoli; Lavinia Morosi
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

6.  Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples.

Authors:  Alice Ly; Rémi Longuespée; Rita Casadonte; Petra Wandernoth; Kristina Schwamborn; Christine Bollwein; Christian Marsching; Katharina Kriegsmann; Carsten Hopf; Wilko Weichert; Jörg Kriegsmann; Peter Schirmacher; Mark Kriegsmann; Sören-Oliver Deininger
Journal:  Proteomics Clin Appl       Date:  2019-01-04       Impact factor: 3.494

7.  MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.

Authors:  Masanobu Nishidate; Kaname Yamamoto; Chinami Masuda; Hiroaki Aikawa; Mitsuhiro Hayashi; Takehiko Kawanishi; Akinobu Hamada
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

8.  Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.

Authors:  Laura Jacobs; Stefan Habringer; Jolanta Slawska; Katharina Huber; Elke Hauf; Zhoulei Li; Yosef Refaeli; Markus Schwaiger; Martina Rudelius; Axel Walch; Ulrich Keller
Journal:  Oncotarget       Date:  2017-08-24

Review 9.  Mass Spectrometry Imaging and Integration with Other Imaging Modalities for Greater Molecular Understanding of Biological Tissues.

Authors:  Tiffany Porta Siegel; Gregory Hamm; Josephine Bunch; Jo Cappell; John S Fletcher; Kristina Schwamborn
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

Review 10.  Spatial heterogeneity of nanomedicine investigated by multiscale imaging of the drug, the nanoparticle and the tumour environment.

Authors:  Josanne Sophia de Maar; Alexandros Marios Sofias; Tiffany Porta Siegel; Rob J Vreeken; Chrit Moonen; Clemens Bos; Roel Deckers
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.